Microvast Holdings announces departure of chief financial officer
FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ: NEO), a provider of cancer testing services with annual revenue of $672 million and healthy liquidity metrics, has introduced a new diagnostic assay, c-MET CDx for NSCLC, designed to expedite the selection of targeted therapies for patients with advanced non-small cell lung cancer (NSCLC). According to InvestingPro analysis, the company maintains a strong current ratio of 2.05, indicating solid operational stability. The test, which identifies c-Met protein overexpression, is now available across the United States with a 48-hour turnaround time.
The c-MET CDx for NSCLC assay is a companion diagnostic immunohistochemistry (IHC) test that aids in determining eligibility for MET-directed therapies, including the recently FDA-approved EMRELIS™ (telisotuzumab vedotin-tllv) for adults with previously treated advanced NSCLC with high c-MET protein overexpression. This approval was granted on May 14, 2025. The company’s stock, currently trading below its InvestingPro Fair Value, has shown revenue growth of 10.1% over the last twelve months, reflecting its expanding market presence.
Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics, emphasized the importance of accurate and timely biomarker testing in lung cancer treatment. He stated that the new assay is a significant addition to their testing portfolio, assisting oncologists in identifying patients who may benefit from MET-directed therapies quickly.
The c-MET CDx for NSCLC assay has been developed in accordance with FDA guidance and validated for use with MET-targeted therapies. It is designed for use with tumor tissue samples to detect MET protein overexpression. Moreover, it complements NeoGenomics’ broader PanTracer™ suite, which provides comprehensive biomarker profiling for NSCLC.
NeoGenomics’ comprehensive NSCLC testing portfolio, which now includes the c-MET CDx for NSCLC assay, supports the growing use of MET-directed therapies and reflects ongoing efforts to align diagnostic services with emerging standards in precision cancer care.
The company, headquartered in Fort Myers, FL, operates a network of CAP-accredited and CLIA-certified laboratories in the U.S. and a CAP-accredited laboratory in Cambridge, United Kingdom. With a gross profit margin of 44.3%, NeoGenomics specializes in cancer genetics testing and information services, offering a comprehensive oncology-focused testing menu to various healthcare providers. For deeper insights into NeoGenomics’ financial health and growth prospects, including 10 additional ProTips and comprehensive valuation metrics, explore the full company analysis available on InvestingPro.
This news is based on a press release statement from NeoGenomics, Inc. and does not include any forward-looking statements or projections provided by the company.
In other recent news, NeoGenomics reported its Q1 2025 earnings, revealing a revenue of $168 million, which fell short of the forecasted $171.35 million. Despite the revenue miss, the company’s earnings per share (EPS) stood at $0, surpassing the forecasted -$0.01. The company maintained its full-year revenue guidance, projecting a 13-15% growth, with expectations for continued growth in its next-generation sequencing (NGS) products. NeoGenomics also fully repaid its 1.25% Convertible Senior Notes ahead of their May 2025 maturity, using its available cash reserves to settle the $201.25 million principal amount. This move reflects the company’s financial management and liquidity strength. Furthermore, NeoGenomics recently acquired Pathline, a New York State-approved lab, which is expected to contribute $12-$14 million in revenue in 2025. However, the integration of Pathline is anticipated to lower adjusted gross margins and adjusted EBITDA for the remainder of the year. Lastly, analysts from William Blair and Morgan Stanley have shown interest in the company’s strategic moves and future growth potential, particularly regarding its oncology solutions and test offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.